Clinical Trial Search

Primary: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment — 6; 3; 7; 7 Participants

Primary: Total Functional Living Index-Emesis (FLIE) Score at Cycle 1 — 109.2 score on a scale

Primary: Change From Baseline Antibiotic Consumption at 18 Months, in Primary Care — 1.71; 2.01 PID-number of packages per 1000 inhabit

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 9; 0 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 7; 7; 5 Participants

Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants

Primary: Heart Rate (HR) — 0.922 Spearman Correlation Coefficient

Primary: Flow-Mediated Dilation (FMD) — 6.11; 5.89; 4.79; 7.31 percentage of arterial diameter

Primary: Measurement of Cold Air Stimulus — 71.4; 72.2; 71.9; 51.1 units on a scale

Primary: Number of Adolescents With Presyncope or Syncope After Vaccination in the Intervention and Usual Care Groups. — 80; 59 Participants — p=0.0249

Primary: Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year) — 1.06093; 1.01563 Fractures per person-year…

Primary: Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration — 11.2; 6.4 months — p=<0.001

Primary: Incidence of Adverse Events — 13; 11; 15 Participants

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Achievement of EASI-50 — 38; 27; 25; 23 Participants